Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

about

Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.Justifiability and Animal Research in Health: Can Democratisation Help Resolve Difficulties?

P2860

Q47268214-D253747B-46A5-4540-A71F-407A8755A854 Q50002245-BB5AAC0B-A44E-47CB-B0EA-8B1AFD95494F

P2860

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

Item

http://www.wikidata.org/entity/Q39069560

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@en

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@nl

type

Item

label

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@en

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@nl

prefLabel

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@en

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@nl

P1476

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

@en

P2860

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease

Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease

Associations between signs and symptoms of dry eye disease: a systematic review

The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)

Tear cytokine profiles in dysfunctional tear syndrome.

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)

P2888

s40265-016-0681-1

P304

201-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-016-0681-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2017-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28058622

http://www.w3.org/2001/XMLSchema#string

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

about

P2860

P2860

Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698